Benzinga | Jan 25, 2021 08:33AM EST

Soligenix To Host Investor Webcast Event On Tuesday, Jan. 26, 2021 From 2:30-4 p.m. EST Related To US Conmmercial Planning For SGX301 In Treatment Of Cutaneous T-Cell Lymphoma

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be hosting an Investor Webcast Event on Tuesday, January 26, 2021 from 2:30-4:00 PM Eastern Standard Time (EST) regarding United States (U.S) commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL).

SGX301 (synthetic hypericin) is a novel first-in-class photodynamic therapy for first-line treatment of early stage CTCL. In the recently completed pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial, SGX301 achieved a statistically significant treatment response rate (p=0.04) in the primary endpoint after just 6 weeks (Cycle 1) of therapy when compared to placebo. This positive treatment response continued to significantly improve with extended SGX301 treatment in the open-label treatment cycles after 12 weeks (Cycle 2) and 18 weeks (Cycle 3) total treatment, reinforcing the positive SGX301 primary endpoint treatment response demonstrated in Cycle 1. In addition, SGX301 has demonstrated a statistically significant response in both patch and plaque lesions through 12 weeks of treatment (Cycle 2), highlighting the unique benefit of using visible light with its deeper skin penetration. SGX301 was well tolerated throughout the study and no mutagenic risks have been identified, unlike other second-line or off-label treatments, including other phototherapies, which utilize ultraviolet light. The Company believes SGX301 has compelling competitive advantages over existing therapies for early stage CTCL and represents a significant near-term commercial opportunity.

Conference Call Tuesday, January 26, 2021 from 2:30-4:00 PM EST

The Company will share information about its commercialization plans in the U.S. for SGX301 on Tuesday, January 26, 2021. A question and answer (Q&A) session with the featured experts and management will follow the presentations. If you would like to ask a question during the Q&A, please submit your request via email to ir@soligenix.com at least 15 minutes prior to the scheduled start of the call.

Live Event: https://sqps.onstreamsecure.com/origin/enliven/players/Soligenix.html

An mp4 recording of the presentation will be archived for 30 days following the event.

This Investor Event will include presentations from the following:

Dr. Ellen Kim, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine and Lead Investigator of the FLASH study;

Dr. Brian Poligone, Director, Rochester Skin Lymphoma Medical Group and lead enroller in the FLASH study;

Mr. Michael Young, Principal, biomedwoRx: Life Sciences Consulting and member of the Cutaneous Lymphoma Foundation Board of Directors;

Mr. Dan Ring, Vice President, Business Development & Strategic Planning of Soligenix; and

Dr. Christopher J. Schaber, President and Chief Executive Officer of Soligenix.